Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

XPhyto Therapeutics takes a major step forward launching first commercial Biosensor for Oral Inflammation

XPhyto Therapeutics takes a major step forward launching first commercial Biosensor for Oral Inflammation

XPhyto Therapeutics CEO Hugh Rogers joined Steve Darling from Proactive to share details the company and their partner 3a-diagnostics have successfully registered their first biosensor test in oral inflammation with the German authorities.

Rogers telling Proactive this will be an at-home self-check that can be performed without the need for specific medical knowledge or training, analytical equipment or even a power supply.

Roger saying, this biosensor, placed on the tongue, the thin film dissolves and, after 5 minutes, the biosensor releases a bitter taste in case of oral inflammation.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK